BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29697008)

  • 1. Incorporation of p-53 mutation status and Ki-67 proliferating index in classifying Her2-neu positive gastric adenocarcinoma.
    Ahmed A; Al-Tamimi DM
    Libyan J Med; 2018 Dec; 13(1):1466573. PubMed ID: 29697008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of Her3 in gastric cancer and its association with molecular prognostic markers: a Saudi cohort based study.
    Ahmed A
    Libyan J Med; 2019 Dec; 14(1):1574532. PubMed ID: 30915908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoexpression of PTEN, HER2/neu, and Ki-67 in endoscopic gastric carcinoma biopsies; their correlation with histological subtypes and one-year survival.
    Acharya S; Thakur B; Mittal R
    Indian J Pathol Microbiol; 2022; 65(1):29-34. PubMed ID: 35074962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Human Epidermal Growth Factor Receptor (Her 2/neu) and Proliferative Marker Ki-67: Association with Clinicopathological Parameters in Gallbladder Carcinoma.
    Pujani M; Makker I; Makker A; Jetley S; Goel MM; Jetley S
    Asian Pac J Cancer Prev; 2016; 17(8):3903-9. PubMed ID: 27644637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Expression of p53, CD44, Ki-67, and HER-2/neu Markers in Gastric Cancer and Its Association with Histopathological Indicators: A Retrospective Study.
    Ahadi M; Moradi A; Musavinejad L; Movafagh A; Moradi A
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1607-1614. PubMed ID: 32592354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical expression of FOXP3 in gastric carcinoma; its relation to Ki-67 proliferation marker, HER2/neu expression, and other clinicopathological parameters.
    Abd-Allah MYY; Abdel-Salam RA; Refat S
    J Immunoassay Immunochem; 2022 Mar; 43(2):1959341. PubMed ID: 34806545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases.
    Barbashina V; Benevenia J; Aviv H; Tsai J; Patterson F; Aisner S; Cohen S; Fernandes H; Skurnick J; Hameed M
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):610-6. PubMed ID: 12458341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system.
    Farzand S; Siddique T; Saba K; Bukhari MH
    World J Gastroenterol; 2014 May; 20(19):5889-96. PubMed ID: 24914350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.
    Koopman T; Smits MM; Louwen M; Hage M; Boot H; Imholz AL
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1343-51. PubMed ID: 25544671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray.
    Ismail HM; Moneer M; El-Baradie M; Khorshid O; Touny A
    J Egypt Natl Canc Inst; 2007 Jun; 19(2):147-57. PubMed ID: 19034345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
    Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
    Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma.
    Xu CC; Yue L; Wei HJ; Zhao WW; Sui AH; Wang XM; Qiu WS
    Pathol Res Pract; 2013 Aug; 209(8):479-85. PubMed ID: 23822993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of
    Pandey I; Misra V; Pandey AT; Verma A
    Indian J Pathol Microbiol; 2022; 65(1):35-41. PubMed ID: 35074963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
    Elkablawy MA; Albasri AM; Mohammed RA; Hussainy AS; Nouh MM; Alhujaily AS
    Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.
    Ivkovic-Kapicl T; Knezevic-Usaj S; Djilas-Ivanovic D; Panjkovic M
    In Vivo; 2007; 21(4):673-8. PubMed ID: 17708365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor, progesterone receptor, HER2/neu, P53 and Ki-67 status of male breast carcinomas in Pakistan.
    Jamal S; Mushtaq H; Mubarik A; Malik TM
    Asian Pac J Cancer Prev; 2009; 10(6):1067-70. PubMed ID: 20192585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma].
    Song Y; Huang J; Wang JW
    Chin J Cancer; 2010 Jan; 29(1):76-81. PubMed ID: 20038314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 status in Gastric and Gastroesophageal Junction Adenocarcinoma.
    Rima FA; Hussain M; Haque N; Dewan RK; Rahman N; Jinnah MA; Jeba R; Chowdhury F
    Mymensingh Med J; 2017 Apr; 26(2):372-379. PubMed ID: 28588175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
    Hechtman JF; Polydorides AD
    Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages.
    Cho J; Jeong J; Sung J; Sung CO; Kim KM; Park CK; Choi MG; Sohn TS; Bae JM; Kim S
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S477-84. PubMed ID: 23274580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.